OSR Holdings Executes Definitive $815 Million Global License Agreement for VXM01 with BCM Europe

About this update from Osr Holdings, Inc.

Largest shareholder pledges entire equity stake as collateral for milestone obligations, reinforcing alignment with public shareholders BELLEVUE, WA / ACCESS Newswire / April 29, 2026 / OSR Holdings, Inc. (NASDAQ:OSRH) today announced that it has entered into a definitive global exclusive license agreement (the "Agreement") with BCM Europe AG ("BCME") for the development, commercialization, and potential sublicensing of VXM01, its Phase 3-ready oral immunotherapy targeting VEGFR-2. The Agreement builds on the previously disclosed binding term sheet and establishes a structured framework to advance VXM01, with alignment across OSRH, its largest shareholder BCME, and public shareholders. "This agreement establishes a clear, accountable framework for the development of VXM01," said Peter Hwang, CEO of OSRH. "It ensures OSR Holdings shareholders participate directly in value creation, while BCME remains accountable for its financial commitments." Transaction Overview BCME is the Company's largest shareholder. Accordingly, the Agreement constitutes a related party transaction and was approved by the Board, including independent directors, following consideration of an independent fairness opinion provided by Avance Life Sciences. Taken together, these economics position OSRH to capture the long-term value created through VXM01's development and commercialization. Alignment Through Equity Pledge Under a separate Pledge Agreement, BCME and affiliates have pledged their entire unencumbered shareholding in OSRH, representing approximately 29.7% as of the signing date, as collateral for the performance of milestone payment obligations of up to $815 million. This structure is designed to: "The decision by BCME to pledge its entire stake as collateral reflects strong conviction in the clinical and commercial potential of VXM01," said Tim Smith, Head of Investor Relations. "It aligns all shareholders around advancing this program toward commercialization and delivering meaningful new treatment options to patients." BCME will actively support development of VXM01 and at the same time engage leading global pharmaceutical partners to secure a sublicensing transaction. With economic returns dependent on downstream monetization and its entire OSRH stake pledged as collateral, BCME is structurally incentivi...

View stock analysis, news, and events for Osr Holdings, Inc.